Effects of Sorafenib on Intrahepatic Circulations in Patients with Advanced Hepatocullar Carcinoma: A Prospective Cohort Study

Effects of Sorafenib on Intrahepatic Circulations in Patients with Advanced Hepatocullar Carcinoma: A Prospective Cohort Study - Effects of Sorafenib on Intrahepatic Circulations

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005410

Enrollment

Registered

2011-05-01

Start date

2009-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Advanced Hepatocellular Carcinoma

Interventions

Sorafenib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Advanced HCC (2) Child-Pugh score <7

Exclusion criteria

Exclusion criteria: (1)Patients who have tumor thrombus in main and/or right portal vein; (2) Ongoing pharmacological therapy for portal hypertension with nonselective beta blocker, nitrates and angiotensin II type 1 receptor blocker (ARB); (3) drinking alcohol within 3 months before the start of the study; (4) History of liver transplantation; (5) Pregnancy, and allergy or past adverse reaction to drugs.

Design outcomes

Primary

Measure	Time frame
Changeses of portal venous area before and after administration of sorafenib	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026